Maternal Vitamin D for Infant Growth (MDIG) Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

1,300

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2018

Conditions
Pregnancy
Interventions
DIETARY_SUPPLEMENT

Vitamin D3 (cholecalciferol)

The intervention is an oral tablet containing vitamin D3 (cholecalciferol). This vitamin D supplement will be provided in the form of small tablets (approximately 10 mm diameter) and will be custom- manufactured by Toronto Institute for Pharmaceutical Technology (TIPT) in Toronto, Ontario, Canada. Each weekly dose will consist of a single tablet. Across trial groups, the tablets will only vary with respect to the vitamin D3 dose, as described above.

DIETARY_SUPPLEMENT

Placebo

This product will be identical in appearance, taste and texture to the experimental formulation but will not include any vitamin D3.

Trial Locations (1)

Unknown

International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka

All Listed Sponsors
collaborator

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

collaborator

Shimantik

UNKNOWN

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

The Hospital for Sick Children

OTHER

NCT01924013 - Maternal Vitamin D for Infant Growth (MDIG) Trial | Biotech Hunter | Biotech Hunter